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With an estimated 350–400 million people worldwide chronically infected with hepatitis B virus
(HBV), and the subsequent serious complications caused by liver damage including cirrhosis,
liver failure, and hepatocellular carcinoma, HBV infection remains a global health issue, particularly
in Taiwan, an HBV-hyperendemic area. Sensitive and accurate quantification of HBV DNA is
necessary to monitor patients with chronic hepatitis B who are receiving antiviral therapy to
determine treatment response and adapt therapy. We evaluated and compared the clinical per-
formance of two HBV DNA assays based on different technologies: the RealArt™ HBV™ PCR Kit
(Abbott HBV DNA PCR kit, real-time polymerase chain reaction assay, detection limit: 27 IU/mL)
and the VERSANT bDNA 3.0 assay (Bayer, branched DNA signal amplification assay, detection
limit: 357 IU/mL). Serum levels of HBV DNA in 173 chronic HBV carriers were determined using
both the RealArt™ HBV™ PCR Kit and the VERSANT bDNA 3.0 test. Of the 173 samples analyzed
for baseline viral load detection, HBV DNA was quantifiable in 147 patients (82.1%) by the
RealArt™ HBV™ PCR Kit, which was significantly higher than the 92 (53.2%) samples quantified
by the VERSANT bDNA 3.0 assay. A total of 86 (49.7%) samples were quantifiable by both assays,
whereas 25 (14.5%) were below the detection limit of both assays. The HBV DNA quantification
values measured by the RealArt™ HBV™ PCR Kit and the VERSANT bDNA 3.0 assay were pos-
itively correlated (Spearman’s rank correlation coefficient r=0.932, p<0.001). On average, the results
derived from the RealArt™ HBV™ PCR Kit were 0.67 log lower than those of the VERSANT
bDNA 3.0 assay. HBV DNA concentrations were significantly higher in 63 HBV e antigen (HBeAg)-
seropositive patients than in 110 HBeAg-seronegative patients (5.42 ± 2.34 logs vs. 3.21 ± 2.27 logs,
p < 0.001). The RealArt™ HBV™ PCR Kit is more sensitive and has a wider dynamic range than
the VERSANT bDNA 3.0 assay in the clinical setting of chronic hepatitis B patients. The sensitivity
and wide dynamic range of the PCR assay allow optimal monitoring and timely adaptation of
antiviral therapy. Nevertheless, the HBV DNA values measured by the RealArt™ HBV™ PCR
Kit and the VERSANT bDNA 3.0 assay were significantly correlated.
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An estimated 350–400 million people worldwide are
infected with hepatitis B virus (HBV), which is one of
the leading causes of death worldwide [1]. In Taiwan,
where HBV infection is hyperendemic [2,3] and is
mainly vertically transmitted, HBV is the most impor-
tant agent responsible for chronic liver disease. Most
of the infections are asymptomatic and cause subse-
quent serious complications, including cirrhosis, liver
failure and hepatocellular carcinoma [4,5]. Recent stud-
ies have demonstrated a direct link between HBV viral
load and the risk of developing disease complications
such as cirrhosis and hepatocellular carcinoma [6]. In
infected individuals, antiviral drugs such as lamivu-
dine [7], adefovir [8,9] and entecavir [10] are effective
in reducing the viral load, normalizing liver function
and consequently reduce the incidence of long-term
complications [11]. However, these treatments do not
generally allow complete eradication of HBV from the
patients, and continuous long-term therapy is required
to maintain effective viral suppression and symptom
control [12]. In addition, the long-term effectiveness of
these drugs is compromised by the emergence of resis-
tant strains, which allows viral breakthrough and
resumption of disease activity [13]. Furthermore, the
current standard of care is to adapt antiviral therapy
in patients with drug resistance as early as possible,
namely at the time of viral breakthrough, as defined
by an increase in viremia levels by 1 log unit of
copies/mL compared with the nadir value [14].
Although numerous tests have been developed to
diagnose and monitor the course and outcome of
chronic liver disease caused by HBV infection, direct
detection of HBV DNA in serum is considered to be
the most reliable method to diagnose infection, partic-
ularly for some HBV genetic variations [15] or occult
HBV infection [16,17].
The first assays developed to measure HBV DNA
were based on membrane hybridization or solution
hybridization of a radiolabeled probe to the dena-
tured strand of HBV DNA in the serum [18]. Then,
nonradioactive hybridization assays based on chemi-
luminescent probes were developed to overcome the
disadvantages of radioisotopes. The branched DNA
(bDNA) assay, which can detect the HBV DNA level
at the lower limit of detection (LLOD) of 0.7 × 106
equivalents/mL, was reported to be better than other
assays for measurement of samples with low HBV
DNA levels [19,20]; this assay was used as the stan-
dard to measure HBV DNA in an antiviral trial [21].
However, in this assay, the LLOD is still too high to
allow detection of lower viral load in some patients,
particularly those who respond to antiviral treatment.
It was found that pronounced decreases in HBV DNA
after treatment were related to better clinical outcomes,
whereas a persistent rebound in viral replication may
indicate the selection of drug-resistant viruses in
patients receiving antiviral therapy [21,22]. Thus, a
more sensitive assay of HBV DNA is needed for the
evaluation of patients.
Methods to assess HBV DNA by quantitative poly-
merase chain reaction (PCR) have been developed
[23,24]. The RealArt™ HBV™ PCR Kit (RealArt Test;
Artus Biotech, Hamburg, Germany) is an automatic,
PCR-based assay of HBV DNA in serum. In our study,
we measured the concentrations of HBV DNA using
the RealArt™ HBV™ PCR Kit in Taiwanese patients
with chronic HBV infection. The performance charac-
teristics and clinical usefulness of the RealArt™
HBV™ PCR Kit were evaluated, and the correlation
between this assay and the VERSANT bDNA 3.0 assay
to measure HBV DNA levels was examined.
METHODS
Patients and serum samples
A total of 173 Taiwanese treatment-naïve patients with
chronic hepatitis B were enrolled in this study. All
patients were seropositive for hepatitis B surface anti-
gen for more than 6 months, and all of these patients
were tested for hepatitis B e antigen (HBeAg) by
radioimmunoassay (General Biological Cooperation,
Hsinchu, Taiwan). All serum samples were separated
from whole blood, collected in serum separation tubes,
and stored immediately at –70°C in several aliquots.
Alanine aminotransferase (ALT) concentrations (nor-
mal upper limit of serum ALT, 40 IU/L) and aspartate
aminotransferase (AST) concentrations (normal upper
limit of serum AST, 42 IU/L) were measured on a
multichannel autoanalyzer. All samples were nega-
tive for antibodies to hepatitis C virus (HCV) accord-
ing to the third-generation HCV antibody (anti-HCV)
enzyme immunoassay test (Abbott Laboratories,
North Chicago, IL, USA).
Measurement of serum HBV DNA
Serum HBV DNA levels were measured by two assays,
the VERSANT bDNA 3.0 assay (Bayer Diagnostics,
Tarrytown, NY, USA) and the RealArt™ HBV™ PCR
assay (Applied Biosystems, Branchburg, NJ, USA)
according to the manufacturer’s instructions.
VERSANT bDNA 3.0 assay
Briefly, HBV genomic DNA is captured onto a micro-
well by a set of specific, synthetic oligonucleotide cap-
ture probes during an overnight incubation. A set of
target probes is also added. The capture probes and
the target probes bind to the HBV genome. A preampli-
fier probe that hybridizes to the target probes is then
added. The amplifier probe subsequently hybridizes
to the preamplifier, forming a bDNA complex. Multi-
ple copies of an alkaline phosphatase-labeled probe
are then hybridized to this immobilized complex.
Detection is achieved by incubating the alkaline
phosphatase-labeled complex with a chemilumines-
cent substrate. Light emission is directly related to
the amount of HBV DNA present in each sample, and
results are recorded as relative light units by the Bayer
System 340 bDNA Analyzer. The dynamic range of
HBV DNA measurements was 357–17,857,100 IU/mL.
RealArt™ HBV™ PCR assay
The HBV™ Master contains reagents and enzymes
for the specific amplification of a 134-bp region of 
the HBV virus genome. The QIAamp DSP Virus Kit
(Qiagen Inc., Valencia, CA, USA) is used for DNA iso-
lation according to the manufacturer’s instructions.
The RealArt™ HBV™ PCR constitutes a ready-to-use
system for the detection of HBV DNA using PCR in
the ABI PRISM® 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Briefly,
30 μL of the Power SYBR Green Master Mix is added
to each required reaction tube or well of the 96-well
reaction plate. Subsequently, 20 μL of the eluate from
the DNA isolation is added to each well. The solution
is mixed well by repeated up-and-down pipetting.
The reaction tubes are closed with the corresponding
caps and centrifuged (in a storage rack for PCR tubes)
for 30 seconds at 1,780g (4,000 revolutions/minute) 
to collect the prepared reaction volume in the bottom
of the tube. If this type of centrifuge is not available,
both the master mix and the sample volume should
be pipetted to the bottom of the tubes. The prepared
reactions are stored at + 4°C until the ABI PRISM®
SDS Instrument is programmed; then the reactions
are transferred into the instrument. The amplicon is
detected by measuring the FAM fluorescence. In
addition, the RealArt™ HBV™ PCR assay contains a
second heterologous amplification system to identify
possible PCR inhibition. This is detected as an inter-
nal control by measuring the JOE (6-carboxy-4’,5’-
dichloro-2’,7’-dimethoxyfluorescein) fluorescence. The
internal control can optionally be used exclusively to
check for possible PCR inhibition. The detection limit
and the linearity range of the RealArt™ HBV™ PCR
assay are 27 IU/mL and 9–4 × 109 IU/mL, respectively.
Statistical analysis
All HBV DNA results are expressed as mean ± stan-
dard deviation (SD) after logarithmic transformation
of the original values. The χ2 test with Yates’ correc-
tion, Fisher’s exact test, Student’s t test, Pearson corre-
lation coefficients, simple linear regression, stepwise
multiple linear regression and multiple logistic regres-
sion were used as appropriate. Results were deemed
significant if p values were less than 0.05.
RESULTS
Background of the 173 patients
The clinical characteristics of the 173 patients, aged
35.5 ± 13.5 years (range, 17–76 years), are shown in
Table 1. The mean ± SD ALT and AST concentrations
were 145.5 ± 269.0 and 231.9 ± 416.4 IU/L, respectively
(Table 1). Sixty-three (36.4%) patients were positive
for HBeAg. Serum HBV DNA levels were significantly
higher in patients with abnormal AST and ALT levels
HBV DNA quantification with PCR kit and bDNA
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and positive HBeAg by both VERSANT bDNA 3.0
assay and RealArt™ HBV™ PCR Kit (all p < 0.001;
Table 1).
Quantitative results of HBV DNA
Eighty-six (49.7%) of 173 samples were quantifiable
by both assays, whereas 25 (14.5%) were below the
detection limit of both assays. Seventeen of 42 (40.5%)
samples with HBV DNA values below the LLOD for
the VERSANT bDNA 3.0 assay could be measured by
the RealArt™ HBV™ PCR Kit. Six HBeAg-negative
samples that could not be measured by the RealArt™
HBV™ PCR Kit were measurable by the VERSANT
bDNA 3.0 assay. All 39 samples (31 HBeAg-positive
and 8 HBeAg-negative) with HBV DNA values higher
than the upper limit of quantification (ULOQ) for
VERSANT bDNA 3.0 assay (17,857,100 IU/mL) were
successfully measured by the RealArt™ HBV™ PCR
Kit. The successful rate of quantification was signifi-
cantly higher with the RealArt™ HBV™ PCR Kit than
with the VERSANT bDNA 3.0 assay for 63 HBeAg-
positive samples (92.1% [58 of 63] vs. 39.7% [25 of 63],
p < 0.001) and 110 HBeAg-negative samples (76.4%
[84 of 110] vs. 60.9% [67 of 110], p = 0.014). The concen-
tration of HBV DNA was higher than the ULOQ 
of the VERSANT bDNA 3.0 assay in 31 of 63 HBeAg-
positive patients. In addition, HBV DNA could not
be measured in 42 (38.2%) of 110 HBeAg-negative
samples by the VERSANT bDNA 3.0 assay, because
the DNA level was below the LLOD (< 357 IU/mL).
However, the RealArt™ HBV™ PCR Kit successfully
measured 58 (92.1%) of 63 HBeAg-positive samples.
Sixty-one (91.0%) of the 67 HBeAg-negative samples
measurable by the VERSANT bDNA 3.0 assay could
also be measured by the RealArt™ HBV™ PCR Kit,
and 17 (40.5%) of the 42 samples with HBV DNA
values below the LLOD for the VERSANT bDNA 3.0
assay could be measured by the RealArt™ HBV™ PCR
Kit. The overall frequency of HBV DNA measurement
for the RealArt™ HBV™ PCR Kit was 82.1%, which
was significantly higher than that for the VERSANT
bDNA 3.0 assay (53.2%, p = 0.001; Figure 1). The con-
trol samples could not be measured by either assay.
Correlation of RealArt™ HBV™ PCR Kit
and VERSANT bDNA 3.0 assay
In the 86 samples successfully measured by both
assays (excluding 48 low-titer and 39 high-titer sam-
ples for the VERSANT bDNA 3.0 assay and the
RealArt™ HBV™ PCR Kit, respectively), there was 
a positive correlation between the two assays (r =
0.932; p = 0.0001; Figure 2). Accordingly, the formula
derived for the conversion of results is as follows:
log(HBV DNA value by RealArt™ HBV™ PCR
Kit) = 1.0086 × log(HBV DNA value by bDNA 3.0
assay) – 0.6624. On average, the results derived from
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Table 1. Backgrounds of hepatitis B virus (HBV)-infected patients and their serum HBV DNA levels measured by
VERSANT bDNA 3.0 assay and RealArt™ HBV™ PCR Kit*
Characteristics
Mean ± SD VERSANT bDNA
p
RealArt™ HBV™
p
or n (%) 3.0 assay† PCR Kit†
All patients 173 4.69 ± 2.01 3.96 ± 2.60
Sex 0.132 0.183
Male 140 (80.9) 4.58 ± 2.01 3.84 ± 2.61
Female 33 (19.1) 5.16 ± 1.94 4.50 ± 2.40
AST 145.47 ± 268.94 < 0.001 < 0.001
Normal (≤ 42 IU/L) 77 (44.5) 3.76 ± 1.84 2.86 ± 2.46
Abnormal (> 42 IU/L) 96 (55.5) 5.47 ± 1.82 4.85 ± 2.32
ALT 231.90 ± 416.41 < 0.001 < 0.001
Normal (≤ 40 IU/L) 54 (31.2) 3.59 ± 1.76 2.86 ± 2.46
Abnormal (> 40 IU/L) 119 (68.8) 5.19 ± 1.92 4.61 ± 2.43
Hepatitis B e antigen < 0.001 < 0.001
Negative 110 (63.6) 4.06 ± 1.80 3.11 ± 2.32
Positive 63 (36.4) 5.78 ± 1.89 5.46 ± 2.33
*Data presented as mean ± standard deviation (SD) or n (%); †expressed as mean ± SD of logarithmic transformation of log IU/mL.
AST = aspartate aminotransferase; ALT = alanine aminotransferase.
the RealArt™ HBV™ PCR test were 0.67 log lower
than the bDNA values (Table 2). The mean differences
between the two assays did not differ between sam-
ples that were positive or negative for HBeAg.
Association between viral load and 
clinical characteristics
Of the 173 patients, the mean ± SD HBV DNA and
ALT and AST values were 3.96 ± 2.60 log IU/mL, 
and 240.4 ± 421.4 and 150.2 ± 272.5 IU/L, respectively.
The ALT concentrations of 96 patients (55.5%) were
abnormal. The association between HBV viral load
and clinical characteristics of HBV infection was eval-
uated. The median HBV DNA concentrations of the
HBeAg-positive and HBeAg-negative samples, as
assessed by the RealArt™ HBV™ PCR Kit, were 3.11±
2.32 log IU/mL and 5.46±2.33 log IU/mL, respectively
(Figure 3). According to univariate analyses, the HBV
DNA values were significantly higher in HBeAg-
positive than in HBeAg-negative patients (p < 0.001;
Table 1), higher in patients with an abnormal ALT
concentration than in those with a normal ALT 
concentration (4.61 ± 2.43 log IU/mL vs. 2.54 ± 2.34 log
IU/mL; p < 0.001), and higher in patients with an
abnormal AST concentration than in those with a
normal AST concentration (4.85 ± 2.32 log IU/mL vs.
2.86 ± 2.46 log IU/mL; p < 0.001). No significant asso-
ciation between HBV DNA value and sex or age was
observed. Multivariate analysis revealed that HBeAg
status and ALT value were associated with HBV DNA
concentrations (both p<0.0001). The serum HBV DNA
concentration was the only factor associated with
ALT value (odds ratio, 1.70; 95% confidence interval,
1.30–2.1).
Comparison of the VERSANT bDNA 3.0 assay
and the RealArt™ HBV™ PCR Kit resulted in patient
population patterns. The number and proportion of
samples with levels of HBV DNA that were below
the LLOD or within various ranges were compared
(Table 3). Lower levels of HBV DNA that could not be
HBV DNA quantification with PCR kit and bDNA
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>ULOQ of bDNA#: *bDNA(−), PCR kit(+), n = 39
Measurable by both assays: bDNA(+), PCR kit(+), n = 86
<LLOD of bDNA§: bDNA(−), PCR kit(+), n = 17
<LLOD of bDNA: bDNA(−), PCR kit(−), n = 25
 bDNA(+), PCR kit(−), n = 6
Total serum samples,
n = 173 
HBeAg(+), n = 31
HBeAg(−), n = 8
HBeAg(+), n = 25
HBeAg(−), n = 61
HBeAg(−), n = 6
HBeAg(+), n = 0
HBeAg(+), n = 2
HBeAg(−), n = 15
HBeAg(+), n = 5
HBeAg(−), n = 20
Figure 1. Flow chart showing the relationship between measurement of hepatitis B virus (HBV) DNA by RealArt™ HBV™ PCR Kit/
VERSANT bDNA 3.0 assay and hepatitis B e antigen (HBeAg) status. bDNA = VERSANT bDNA 3.0 assay; PCR kit = RealArt™
HBV™ PCR Kit; ULOQ of bDNA# = upper limit of quantification of bDNA; LLOD of bDNA§ = lower limit of detection of bDNA;
*bDNA(−), PCR kit(+) = HBV DNA values were not quantifiable by VERSANT bDNA 3.0 assay but were quantifiable by PCR kit;
bDNA(+), PCR kit(−) = VERSANT bDNA 3.0 assay could measure the HBV DNA values of these samples (520, 567, 1,135, 2,614,
4,537 and 7,452 IU/mL), but the PCR Kit could not detect HBV DNA of these serum samples.
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Figure 2. Comparison between hepatitis B virus (HBV) DNA val-
ues in samples from 86 patients with chronic HBV infection that
were quantifiable by both the RealArt™ HBV™ PCR Kit and the
VERSANT bDNA 3.0 assay. There was a good correlation between
all samples yielding values within the quantitative range of each
of the assays. Pearson’s correlation coefficient r = 0.932, p < 0.001.
HBV values are expressed as log IU/mL.
measured by the VERSANT bDNA 3.0 assay (log HBV
DNA 0.5–1, 1–2 IU/mL) could be quantified by the
RealArt™ HBV™ PCR Kit. These results indicate that
the RealArt™ HBV™ PCR Kit has better sensitivity
for lower levels of HBV DNA and a wider dynamic
range.
DISCUSSION
Because HBV infection is endemic in Taiwan, being
able to adequately diagnose and manage patients
with the aid of diagnostic tools, including virological
tests, is important. The viral load varies greatly dur-
ing the different phases of HBV infection, ranging
from undetectable levels to >109 copies/mL. Dramatic
changes may occur in response to antiviral treatment;
therefore, the range of quantitative measurement for
HBV DNA detection assays needs to be wide. Assays
that use signal amplification, including the bDNA
assay (Bayer Diagnostics, Inc.), generally have a wide
dynamic range, but their sensitivity is lower com-
pared with assays based on target amplification (i.e.
PCR-based assays); however, the latter often have 
a restricted dynamic range [25]. Quantitative HBV
DNA assays that use real-time PCR have recently
been developed; these assays are very sensitive and
have a wider linear range compared with PCR- or
bDNA-based assays.
Our study showed a correlation between RealArt™
HBV™ PCR Kit and VERSANT bDNA 3.0 assay for
the detection and quantification of HBV DNA over a
wide range of HBV DNA levels. Both assays shared
significant concordance of values included in the
overlapping dynamic range (r = 0.932, p < 0.001). This
implies that both assays can provide consistent indi-
cations for decision making on the use and adapta-
tion of antiviral therapy. The RealArt™ HBV™ PCR
Kit improved the sensitivity by extending the detec-
tion range; therefore, patients in whom the viral load
was unmeasurable by the VERSANT bDNA 3.0 could
be evaluated. A study by Chan et al [26] revealed that
approximately half of those patients with unde-
tectable HBV DNA values by bDNA assays were 
positive for HBV DNA in an in-house PCR assay. All
HBeAg-positive samples that could be detected by
the VERSANT bDNA 3.0 assay could also be mea-
sured by the RealArt™ HBV™ PCR Kit. We found
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Table 2. Correlation between the results of the RealArt™ HBV™ PCR Kit and the VERSANT bDNA 3.0 assay in 86
samples quantifiable by both assays
HBV DNA value* Spearman’s rank
n VERSANT RealArt™ Difference
†
Correlation 
p
bDNA 3.0 assay HBV™ PCR Kit coefficient
All 86 4.81 ± 1.43 4.19 ± 1.55 0.62 0.947 < 0.001
HBeAg
Positive 25 4.95 ± 1.43 4.36 ± 1.43 0.59 0.930 < 0.001
Negative 61 4.76 ± 1.43 4.12 ± 1.60 0.64 0.902 < 0.001
*Expressed as mean± standard deviation of logarithmic transformation (log IU/mL); †Difference = log(bDNA 3.0 assay) –  log(RealArt™
HBV™ PCR Kit). HBV = hepatitis B virus; HbeAg = hepatitis B e antigen.
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Figure 3. Comparison between hepatitis B virus (HBV) DNA
values in hepatitis B e antigen-negative and -positive samples
from patients with chronic HBV infection measured by the Real-
Art™ HBV™ PCR Kit. CI = confidence interval; HBeAg =
hepatitis B e antigen.
that 40.5% of samples with HBV DNA values below
the LLOD of VERSANT bDNA 3.0 assay and 100% of
samples with HBV DNA values higher than the ULOQ
for the VERSANT bDNA 3.0 assay could be measured
by the RealArt™ HBV™ PCR Kit. Approximately
69.1% of our samples for which the VERSANT bDNA
3.0 assay could not detect measurable HBV DNA
(< LLOD or > ULOQ) were found to contain HBV
DNA by the RealArt™ HBV™ PCR Kit. This PCR
assay was shown to have a higher quantification rate
of HBV DNA values than the VERSANT bDNA 3.0
assay in HBeAg-positive and HBeAg-negative sam-
ples. Our results are in strong agreement with a
recent comparative analysis of the real-time PCR kit
and the VERSANT bDNA 3.0 assay [27]; the sensitiv-
ity and dynamic range of the real-time PCR kit were
superior to that of the VERSANT bDNA 3.0 assay.
Our results were also consistent with studies that
compared other real-time PCR assays and the VER-
SANT bDNA assay [28–30]. Therefore, the RealArt™
HBV™ PCR Kit might be more applicable than the
bDNA 3.0 assay in clinical practice.
In our study, significant differences in HBV DNA
values were found between HBeAg-positive and
HBeAg-negative samples in both assays, and similar
differences have been reported in studies analyzing
real-time PCR and other assays [31–33]. The mean
HBV DNA values were lower in HBeAg-negative
than in HBeAg-positive patients, and the higher rate
of HBV DNA values were below the LLOD of the
bDNA 3.0 assay. The RealArt™ HBV™ PCR Kit, with
higher sensitivity, seems to be more suitable for accu-
rate measurement of HBV DNA values in HBeAg-
negative patients.
In our study, the HBV DNA values derived from
the RealArt™ HBV™ PCR Kit were, on average, 0.67
log lower than the VERSANT bDNA 3.0 values. We
revealed in our previous study that results derived
by an automatic PCR-based assay (the COBAS
AMPLICOR HBV MONITOR test; Roche Molecular
Systems, Pleasanton, CA, USA) were, on average,
0.55 log lower than those of the bDNA assay [34].
HBV DNA values were also significantly associ-
ated with ALT values. A test allows detection of HBV
DNA at a level well below the levels considered nec-
essary for the control of disease or those associated
with an elevated risk of hepatocellular carcinoma. The
latest treatment concept advocates early introduction
of rescue therapy in patients with viral breakthrough,
which is defined as a 10-fold increase in HBV viral
load from the nadir after treatment. This approach
has been demonstrated to provide important benefits
in terms of long-term clinical outcomes [14] and to
adjust therapy during the 1st year when the viral load
is not suppressed below 3 log10 copies/mL [35]. This
real-time PCR test with high sensitivity is well suited
to the new treatment algorithm. Based on our analy-
ses, the RealArt™ HBV™ PCR Kit is more useful
when the HBV DNA values are below the LLOD of a
bDNA assay.
Six HBeAg-negative samples could not be mea-
sured by the RealArt™ HBV™ PCR Kit; however, 
HBV DNA quantification with PCR kit and bDNA
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Table 3. Comparison of results using RealArt™ HBV™ PCR Kit and VERSANT bDNA 3.0 assay at different levels of
hepatitis B virus DNA
Result category (log VERSANT bDNA 3.0 assay RealArt™ HBV™ PCR Kit
HBV DNA IU/mL) No. of samples % Cumulative % No. of samples % Cumulative %
< LLOD*† 44 24.6 24.6 32 17.9 17.9
0.5–1 1 0.6 18.5
1–2 15 8.4 26.9
2–3 13 7.3 31.8 25 14.0 40.9
3–4 23 12.8 44.6 15 8.4 49.3
4–5 17 9.6 54.2 18 10.1 59.4
5–6 14 7.8 62.0 21 11.6 71.0
6–7 23 12.8 74.8 15 8.4 79.4
7–8 45 25.2 100 37 20.6 100
*HBV DNA was not detected or was detected below the limit of detection. For the bDNA 3.0 assay, the limit of detection is 2.255 log
HBV DNA IU/mL (< 357 IU/mL), and for the HBV PCR kit, the limit of detection is 0.301 log HBV DNA IU/mL (< 4 IU/mL).
†Sensitivity in 147 patients (82.1%) measured by the HBV PCR kit was significantly higher than the 135 (75.4%) patients measured 
by the bDNA 3.0 assay (p = 0.01). HBV = hepatitis B virus; LLOD = lower limit of detection.
the VERSANT bDNA 3.0 assay could measure the HBV
DNA values of these samples (520, 567, 1,135, 2,614,
4,537 and 7,452 IU/mL). The reason why RealArt™
HBV™ PCR could not successfully determine the
viral load in these samples deserves further investi-
gation. A recent study [30] has shown some draw-
backs of two widely used assays: (1) Cobas Monitor
has a narrow dynamic range and underestimates
genotype F sample viral loads; and (2) bDNA shows
poor sensitivity and may fail to identify patients with
low viral loads. Because of their higher performance
in terms of analytical sensitivity combined with a
larger dynamic range and an ability to quantify the
main genotypes equally, real-time PCR methods
appear to be more appropriate for accurate HBV
DNA quantification. Furthermore, the impact of HBV
genotyping on the performance of the testing meth-
ods needs to be clarified in further studies.
In conclusion, the results of the RealArt™ HBV™
PCR Kit assay correlated well with those of the VER-
SANT bDNA 3.0 assay. The RealArt™ HBV™ PCR
Kit had higher sensitivity and a wider dynamic range
than the VERSANT bDNA 3.0 assay. This PCR assay
can be used effectively to monitor patients with high
serum HBV DNA levels and will remain effective if
serum HBV DNA levels are decreased to levels that
might be unmeasurable by the VERSANT bDNA 3.0
assay. The sensitivity and wide dynamic range of 
this PCR assay allow optimal monitoring and timely
adaptation of antiviral therapy.
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針對台灣慢性 B 型肝炎患者以 Abbott HBV PCR 
Kit 和 VERSANT HBV DNA 3.0 Test 定量
血清中 HBV DNA 值的臨床應用與比較
楊正福
1,2
  林雅雲
1
  黃志富
2,3
  劉淑芬
2
  褚佩瑜
4
謝明彥
2
  林子堯
2,3
  陳信成
2,3
  王良彥
2,3
戴嘉言
2,3,5
  莊萬龍
2,3
  余明隆
1,2,3
1
高雄醫學大學附設醫院  保健科  
2
內科部  肝膽胰內科  
5
職業環境醫學科
3
高雄醫學大學  醫學院  醫學系
4
健康科學院  醫學檢驗生物技術學系
全球估計約有三億五千萬至四億人感染慢性 B 型肝炎病毒，並導致慢性肝臟損傷，例如肝硬化、肝衰
竭、肝細胞癌等嚴重後遺症。這使得慢性 B 型肝炎病毒感染已經成為全球健康的主要議題之一，尤其
在 B 型肝炎病毒感染盛行的台灣更顯得重要。在接受 B 型肝炎抗病毒治療的過程中，靈敏與精確的 B 
型肝炎病毒 (HBV DNA) 定量分析對治療反應評估與治療策略調整十分重要。因此，在本研究中，我
們比較兩種新一代，但操作原理不同的 HBV DNA 定量分析方法：RealArt ™ HBV ™ PCR Kit 
(Abbott HBV PCR Kit，即時 PCR 分析法 ) 與 VERSANT bDNA 3.0 assay (Bayer branched DNA 
signal amplification assay)，分析這兩者在 HBV DNA 定量的靈敏度、偵測範圍 (sensitivity、
dynamic range) 和臨床應用的優缺點。分別以 RealArt ™ HBV ™ PCR Kit 與 VERSANT bDNA 
3.0 assay 定量分析 173 位慢性 B 型肝炎患者血清中的 HBV DNA 值，並分析 HBV DNA 值與 B 型
肝炎 e抗原 (HbeAg) 帶原情形、血清中 AST、ALT 值的關聯性。在所有 173 位患者的血清中，147 
(82.1%) 個血清樣本可以 RealArt ™ HBV ™ PCR Kit 分析法測得 HBV DNA，明顯的優於 
VERSANT bDNA 3.0 assay 分析法，其只測得了 92 (53.2%) 個血清樣本。這其中，86 (49.7%) 個
血清樣本可同時由 RealArt ™ HBV ™ PCR Kit 與 VERSANT bDNA 3.0 assay 兩種方法測得 HBV 
DNA，而有 25 (14.5%) 個血清樣本因低於兩種方法的偵測值而皆無法測出 HBV DNA。在可同時被
兩種方法定量分析出 HBV DNA 值者，分析的結果顯示兩種方法的定量值線性相關性佳 (Spearman's 
rank correlation coefficient r = 0.932、p < 0.001)。平均而言，以 RealArt ™ HBV ™ PCR Kit 
分析法定量的 HBV DNA 值較以 VERSANT bDNA 3.0 assay 分析法獲得之值低 0.67 log。同時，本
研究亦顯示 B 型肝炎 e抗原陽性患者 (HbeAg(+)) 較 B 型肝炎 e 抗原陰性患者 (HbeAg(–)) 有較高的 
HBV DNA 值 (5.42 ± 2.34 logs vs. 3.21 ± 2.27 logs、p < 0.001)。在偵測 HBV DNA 值上，
RealArt ™ HBV ™ PCR Kit 分析法比 VERSANT bDNA 3.0 assay 分析法更具靈敏度和偵測範圍，
因此在治療慢性 B 型肝炎患者時具更佳的應用性。但，兩個方法所定量分析出的 HBV DNA 值具有明
顯的關聯性。
關鍵詞：bDNA 3.0 assay, HBeAg, HBV DNA PCR Kit, HBV DNA quantification, HBV infection
(高雄醫誌 2009;25:413–22)
